US regulators to weigh controversial peptides backed by RFK Jr

Key Points:

• The US FDA's Pharmacy Compounding Advisory Committee is set to review whether seven peptides, marketed for various health conditions, should be available through licensed compounding pharmacies with prescriptions.
• These peptides, including BPC-157, TB-500, and KPV, are promoted for uses such as ulcerative colitis, wound healing, obesity, migraines, chronic pain, insomnia, and opioid withdrawal, despite limited evidence of their safety and effectiveness.
• The rise in peptide popularity has been driven by social media influencers, wellness trends like "looksmaxxing," and endorsements from Health Secretary Robert F Kennedy Jr., raising concerns about unregulated use in grey markets.
• The advisory committee reviewing these peptides includes members with ties to peptide-related businesses and clinics, prompting controversy over potential conflicts of interest, although the Department of Health and Human Services maintains that ethics reviews were conducted.
• While the committee's recommendations are not binding, they will significantly influence the FDA's final decision on whether these peptides can be compounded and dispensed by licensed pharmacies.